Medical Information

The contraindications of Tazemetostat involve specific populations, dietary interactions, and treatment restrictions, and must be strictly followed to avoid serious adverse reactions. The following provides a detailed explanation from three aspects: the classification of taboo populations, food interactions, and clinical usage restrictions, including the management of special physiological states and key contraindications.

1. Taboo population

(1) Pregnant women: Based on animal teratogenic data, it is absolutely prohibited during pregnancy. Women of childbearing age should take effective contraceptive measures during treatment and 6 months after discontinuing medication.

(2) Breastfeeding period: Medications may cause serious adverse reactions in infants through milk secretion. Breastfeeding is prohibited during the treatment period until one week after the last administration.

(3) Children: Safety and efficacy data for patients under 18 years old have not been established and should be avoided.

2. Forbidden foods

(1) Grapefruit/Seville Orange: Contains strong CYP3A4 inhibitors, which can increase the blood concentration of tazestar by three times and increase the risk of toxicity.

(2) St. John's wort: Inducing CYP3A4 to reduce drug efficacy, avoid simultaneous use.

(3) High fat diet: Postprandial administration can increase AUC by 35%. It is recommended to take on an empty stomach (1 hour before or 2 hours after meals).

3. Restrictive conditions

(1) Liver function impairment: Not recommended for Child Pugh C patients; Child Pugh B grade requires a 50% reduction; Suspend administration if ALT/AST>3 times ULN.

(2) Hematological toxicity: Discontinue treatment when platelet count is less than 50 × 10 ^ 9/L or neutrophil count is less than 1 × 10 ^ 9/L, reduce dosage and restart after recovery.

(3) Drug interactions: Combination use of strong CYP3A4 inducers (such as rifampicin) or inhibitors (such as ketoconazole) is prohibited.

4. Special precautions

(1) Secondary malignant tumors: MDS/AML risk factors need to be evaluated before treatment, and peripheral blood cytogenetics should be monitored every 3 months during treatment.

(2) Fertility impact: may cause ovarian dysfunction, and those who have fertility needs should seek fertility preservation counseling before treatment.